9 Results for "

bystander activity

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "bystander activity" in MCE Product Catalog:

Cat. No.: HY-164729
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
loading...
    loading...
Cat. No.: HY-163099
CAS No.: 2928571-43-9
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
loading...
    loading...
Cat. No.: HY-176976
CAS No.: 3076725-05-5
Research Areas:  

Cancer

Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .
loading...
    loading...
Cat. No.: HY-126218
CAS No.: 111687-37-7
Target:  

HSV

Research Areas:  

Cancer

HSV-TK substrate is a substrate for HSV-TK, and induces multi-log cytotoxicity in HSV-TK-expressing and bystander cells. HSV-TK substrate shows antitumor activity .
loading...
    loading...
Cat. No.: HY-186279
CAS No.: 3135386-37-4
Research Areas:  

Cancer

Pan-RAS-IN-9-(R)-2-Hydroxy-3-methylbutanoic acid-Sar9-N-Lys (Tos)-βAla-GFGG is a drug-linker conjugate for antibody-drug conjugate (ADC) with pan-Ras inhibitory activity. Pan-RAS-IN-9-(R)-2-Hydroxy-3-methylbutanoic acid-Sar9-N-Lys (Tos)-βAla-GFGG can be used in research related to ADC synthesis .
loading...
    loading...
Cat. No.: HY-185742
Research Areas:  

Cancer

ZW-251 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) with topoisomerase-I inhibitory activity. ZW-251 induces cytotoxicity, penetrates tumor spheroids, exerts bystander cytotoxicity, and inhibits tumor growth in hepatocellular carcinoma models. ZW-251 can be used for the research of hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-182623
CAS No.: 2640723-72-2
Target:  

MDM-2/p53

Research Areas:  

Cancer

WB214 is an MDM2 and GSPT1 degrader with human MDM2 Ki >10 μM. WB214 induces a neo-interaction between MDM2 and the cereblon E3 ligase complex, triggering MDM2 ubiquitination, proteasomal degradation, and bystander p53 degradation, and does not bind MDM2’s p53 binding region. WB214 induces GSPT1 degradation, and exhibits anti-proliferative activity in leukemia cells. WB214 can be used for the research of leukemia .
loading...
    loading...
Cat. No.: HY-185816
TQB2102 is a bispecific epitope antibody-drug conjugate targeting HER2, composed of the antibody Rolditamig (HY-P992130) and the toxin molecule Deruxtecan-d2 (HY-13631ES3). TQB2102 binds to the ECD2 and ECD4 domains of HER2, promotes its own internalization by HER2-expressing cells, and delivers deuterated DXd payload to inhibit topoisomerase I. TQB2102 induces antibody-dependent cellular cytotoxicity, DNA damage, bystander killing activity, and inhibits cancer cell proliferation. TQB2102 can be used in research related to various cancers including metastatic breast cancer, colorectal cancer, and gastric/gastroesophageal junction adenocarcinoma .
loading...
    loading...
Cat. No.: HY-185743
ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody (HY-P992515) as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer .
loading...
    loading...